News Headlines Article

Panel pans Avastin as breast cancer treatment
Modern Healthcare

A cancer-drug advisory panel has recommended that the Food and Drug Administration pull its approval of Avastin as a first-line treatment for a specific type of advanced breast cancer. The panel on Tuesday voted 12-1 for the removal of a label indication that identifies Avastin, manufactured by the Roche Group division Genentech, in combination with the chemotherapy drug paclitaxel as a recommended treatment for women with advanced HER2-negative breast cancer.